FI119733B - Menetelmiä sellaisten rekombinantti -IL4-vasta-aineiden valmistamiseksi jotka ovat käyttökelpoisia IL-4-välitteisten häiriötilojen hoidossa - Google Patents

Menetelmiä sellaisten rekombinantti -IL4-vasta-aineiden valmistamiseksi jotka ovat käyttökelpoisia IL-4-välitteisten häiriötilojen hoidossa Download PDF

Info

Publication number
FI119733B
FI119733B FI961083A FI961083A FI119733B FI 119733 B FI119733 B FI 119733B FI 961083 A FI961083 A FI 961083A FI 961083 A FI961083 A FI 961083A FI 119733 B FI119733 B FI 119733B
Authority
FI
Finland
Prior art keywords
seq
human
antibody
sequence
ser
Prior art date
Application number
FI961083A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI961083A0 (fi
FI961083A (fi
Inventor
Mitchell Stuart Gross
Stephen Dudley Holmes
Daniel R Sylvester
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of FI961083A0 publication Critical patent/FI961083A0/fi
Publication of FI961083A publication Critical patent/FI961083A/fi
Application granted granted Critical
Publication of FI119733B publication Critical patent/FI119733B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/247IL-4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869Interleukin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FI961083A 1993-09-07 1996-03-07 Menetelmiä sellaisten rekombinantti -IL4-vasta-aineiden valmistamiseksi jotka ovat käyttökelpoisia IL-4-välitteisten häiriötilojen hoidossa FI119733B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11736693A 1993-09-07 1993-09-07
US11736693 1993-09-07
US13678393A 1993-10-14 1993-10-14
US13678393 1993-10-14
US9410308 1994-09-07
PCT/US1994/010308 WO1995007301A1 (en) 1993-09-07 1994-09-07 Recombinant il4 antibodies useful in treatment of il4 mediated disorders

Publications (3)

Publication Number Publication Date
FI961083A0 FI961083A0 (fi) 1996-03-07
FI961083A FI961083A (fi) 1996-05-06
FI119733B true FI119733B (fi) 2009-02-27

Family

ID=26815208

Family Applications (1)

Application Number Title Priority Date Filing Date
FI961083A FI119733B (fi) 1993-09-07 1996-03-07 Menetelmiä sellaisten rekombinantti -IL4-vasta-aineiden valmistamiseksi jotka ovat käyttökelpoisia IL-4-välitteisten häiriötilojen hoidossa

Country Status (21)

Country Link
EP (1) EP0730609B1 (hu)
JP (4) JPH09502708A (hu)
KR (1) KR100362340B1 (hu)
CN (2) CN1105728C (hu)
AP (1) AP583A (hu)
AT (1) ATE286510T1 (hu)
AU (1) AU695726B2 (hu)
BG (1) BG63549B1 (hu)
BR (1) BR9407575A (hu)
CA (1) CA2171336C (hu)
CZ (1) CZ295928B6 (hu)
DE (1) DE69434223T2 (hu)
ES (1) ES2236693T3 (hu)
FI (1) FI119733B (hu)
HU (1) HU222041B1 (hu)
NO (1) NO960956L (hu)
NZ (1) NZ274338A (hu)
PL (1) PL180125B1 (hu)
SK (1) SK285556B6 (hu)
UA (1) UA48940C2 (hu)
WO (1) WO1995007301A1 (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US6768004B2 (en) * 2001-01-11 2004-07-27 Mueller Sybille Nucleotide sequences encoding variable regions of heavy and light chains of monoclonal antibody 1F7, an anti-idiotypic antibody reactive with anti-HIV antibodies
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
TWI374893B (en) * 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
ATE452147T1 (de) 2004-02-19 2010-01-15 Genentech Inc Antikörper mit korrigierten cdr
PE20060560A1 (es) * 2004-08-03 2006-06-27 Novartis Ag Anticuerpos de interleucina-4 humana
JP2008523815A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのヒト化アミロイドβ抗体
AU2007228943B2 (en) * 2006-03-22 2012-03-22 Apogenix Gmbh Antibody specific for human IL-4 for the treament of cancer
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
ES2371287T3 (es) 2006-06-21 2011-12-29 Apogenix Gmbh Expresión diferencial de la citocina en cáncer humano.
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP4971872B2 (ja) 2007-05-23 2012-07-11 株式会社トプコン 眼底観察装置及びそれを制御するプログラム
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
JP5324839B2 (ja) 2008-06-19 2013-10-23 株式会社トプコン 光画像計測装置
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CN102294024B (zh) * 2011-01-17 2013-03-13 广东现代农业集团研究院有限公司 一种多肽疫苗及其制备方法
CN107614762B (zh) * 2015-02-24 2022-08-05 台湾地区“中央研究院” 一种由噬菌体表达的单链变异片段抗体库
CN113156134B (zh) * 2020-11-26 2024-01-23 江苏荃信生物医药股份有限公司 用于检测人白介素23的elisa试剂盒及检测方法
CN114920845A (zh) * 2020-12-31 2022-08-19 中元汇吉生物技术股份有限公司 特异性结合人IgG4的蛋白及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
JP2646007B2 (ja) * 1988-01-30 1997-08-25 財団法人 化学及血清療法研究所 抗hiv抗体可変領域をコードする遺伝子断片およびこれらを用いて発現された抗hivキメラ抗体ならびにその製法
EP0365209A3 (en) * 1988-10-17 1990-07-25 Becton, Dickinson and Company Anti-leu 3a amino acid sequence
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JPH07119238B2 (ja) * 1989-12-18 1995-12-20 小野薬品工業株式会社 ヒトインターロイキン―4に対するモノクローナル抗体および該抗体の利用方法
KR960016862B1 (ko) * 1989-12-20 1996-12-23 쉐링 코포레이션 사람 인터루킨-4의 특정 잔기 서열로 이루어진 폴리펩타이드 및 이에 대한 항체의 제조방법
JPH04141095A (ja) * 1990-10-02 1992-05-14 Chemo Sero Therapeut Res Inst 組換え抗hiv改変抗体および改変抗体の調製方法
NZ249677A (en) * 1992-02-19 1996-08-27 Schering Corp Monoclonal antibodies and compositions useful for treating il-4 diseases and intermediates for making such antibodies
JPH06269663A (ja) * 1993-03-17 1994-09-27 Toyobo Co Ltd Cd4陽性細胞捕集材
AU6498000A (en) * 1999-07-30 2001-02-19 Battelle Memorial Institute Glass-ceramic joining material and method of joining

Also Published As

Publication number Publication date
NO960956L (no) 1996-05-06
JP2007045831A (ja) 2007-02-22
CA2171336A1 (en) 1995-03-16
KR100362340B1 (ko) 2003-02-26
AP583A (en) 1997-04-14
BG100480A (bg) 1996-12-31
CN1133599A (zh) 1996-10-16
DE69434223D1 (de) 2005-02-10
PL180125B1 (pl) 2000-12-29
FI961083A0 (fi) 1996-03-07
AU695726B2 (en) 1998-08-20
JP2009191077A (ja) 2009-08-27
CZ69896A3 (en) 1996-10-16
BR9407575A (pt) 1996-07-16
FI961083A (fi) 1996-05-06
JPH09502708A (ja) 1997-03-18
PL313491A1 (en) 1996-07-08
HUT75833A (en) 1997-05-28
NO960956D0 (no) 1996-03-07
HU222041B1 (hu) 2003-04-28
CN1105728C (zh) 2003-04-16
ATE286510T1 (de) 2005-01-15
EP0730609B1 (en) 2005-01-05
EP0730609A4 (en) 2000-05-10
SK285556B6 (sk) 2007-03-01
CZ295928B6 (cs) 2005-12-14
CN1473854A (zh) 2004-02-11
WO1995007301A1 (en) 1995-03-16
JP2006333870A (ja) 2006-12-14
AP9600782A0 (en) 1996-04-30
EP0730609A1 (en) 1996-09-11
ES2236693T3 (es) 2005-07-16
BG63549B1 (bg) 2002-04-30
SK33396A3 (en) 1996-10-02
UA48940C2 (uk) 2002-09-16
AU7834094A (en) 1995-03-27
DE69434223T2 (de) 2005-12-22
HU9600616D0 (en) 1996-05-28
NZ274338A (en) 1998-02-26
CA2171336C (en) 2011-06-21

Similar Documents

Publication Publication Date Title
FI119733B (fi) Menetelmiä sellaisten rekombinantti -IL4-vasta-aineiden valmistamiseksi jotka ovat käyttökelpoisia IL-4-välitteisten häiriötilojen hoidossa
EP1299421B1 (en) Antibodies to human mcp-1
EP1163271B1 (en) Recombinant il-18 antibodies and their use
US7807793B2 (en) Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
WO1995001997A1 (en) RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
RU2162711C2 (ru) Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
AU2001283903A1 (en) Antibodies to human MCP-1
HU228159B1 (en) Antibodies to human il-1beta
JP2013091636A (ja) Il−5により媒介される疾病の治療に有用な組み換えil−5アンタゴニスト
US5928904A (en) DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US5914110A (en) Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
JP2001523083A (ja) Il−5により媒介される疾病の治療に有用な組み換えil−5アンタゴニスト
RO116809B1 (ro) Anticorp recombinant, monoclonal, compozitie farmaceutica si metoda de tratament cu aceasta
MXPA01009514A (en) Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 119733

Country of ref document: FI

MM Patent lapsed